Manufacturing Process Development of Tegoprazan as a Potassium-Competitive Acid Blocker (P-CAB)

被引：5

作者：

Kweon, Jae-Hong ^{[1
,2
]}

Shin, Hyungjin ^{[1
]}

Lee, Min Kyoung ^{[2
]}

Lee, Sung Ah ^{[2
]}

Singh, Pargat ^{[1
]}

Moon, Kyeongwon ^{[1
]}

Kim, In Su ^{[1
]}

机构：

[1] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea

[2] HK inno N Corp, Proc Dev Ctr, Icheon 17389, South Korea

来源：

ORGANIC PROCESS RESEARCH & DEVELOPMENT | 2024年 / 28卷 / 04期

基金：

新加坡国家研究基金会;

关键词：

Asymmetric hydrogenation; Manufacturing process; Mitsunobu etherification; Potassium-competitive acid blocker; Tegoprazan; GASTROESOPHAGEAL-REFLUX DISEASE; PUMP INHIBITOR THERAPY; PROTON; DEFINITION; MITSUNOBU; SECRETION; RISK;

D O I：

10.1021/acs.oprd.4c00005

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

Tegoprazan, a selective potassium-competitive acid blocker, was approved in 2018 in the Republic of Korea for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and nonerosive reflux disease (NERD). The complexity of tegoprazan, which contains a 4,6-disubstituted 1H-benzo[d]imidazole core and a chiral chromanol moiety, makes it a challenging molecule to prepare on a commercial scale. An efficient and economical route of the key intermediates and a much improved end-game for tegoprazan were developed.

引用

页码：1159 / 1169

页数：11

共 29 条

[1] Review article: potassium-competitive acid blockers for the treatment of acid-related disorders [J].

Abdel-Aziz, Yousef ;

Metz, David C. ;

Howden, Colin W. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (07) :794-809

[2] Redox-neutral organocatalytic Mitsunobu reactions [J].

Beddoe, Rhydian H. ;

Andrews, Keith G. ;

Magne, Valentin ;

Cuthbertson, James D. ;

Saska, Jan ;

Shannon-Little, Andrew L. ;

Shanahan, Stephen E. ;

Sneddon, Helen F. ;

Denton, Ross M. .

SCIENCE, 2019, 365 (6456) :910-+

[3] DEFINITION AND ANTAGONISM OF HISTAMINE H2-RECEPTORS [J].

BLACK, JW ;

PARSONS, EM ;

DURANT, CJ ;

DUNCAN, WAM ;

GANELLIN, CR .

NATURE, 1972, 236 (5347) :385-&

[4]

Clark D.E., 2001, Chem. Health Saf., V8, P12, DOI [10.1016/S1074-9098(01)00247-7, DOI 10.1016/S1074-9098(01)00247-7]

[5] Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia [J].

de Jager, C. P. C. ;

Wever, P. C. ;

Gemen, E. F. A. ;

van Oijen, M. G. H. ;

van Gageldonk-Lafeber, A. B. ;

Siersema, P. D. ;

Kusters, G. C. M. ;

Laheij, R. J. F. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (10) :941-949

[6] Time trends of gastroesophageal reflux disease: A systematic review [J].

El-Serag, Hashem B. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (01) :17-26

[7]

Hanazawa T., 2007, Patent, Patent No. [2007/072146A1, 2007072146, WO 2007072146]

[8] Proton pump inhibitors affect the gut microbiome [J].

Imhann, Floris ;

Bonder, Marc Jan ;

Vila, Arnau Vich ;

Fu, Jingyuan ;

Mujagic, Zlatan ;

Vork, Lisa ;

Tigchelaar, Ettje F. ;

Jankipersadsing, Soesma A. ;

Cenit, Maria Carmen ;

Harmsen, Hermie J. M. ;

Dijkstra, Gerard ;

Franke, Lude ;

Xavier, Ramnik J. ;

Jonkers, Daisy ;

Wijmenga, Cisca ;

Weersma, Rinse K. ;

Zhernakova, Alexandra .

GUT, 2016, 65 (05) :740-748

[9] THE MECHANISM OF THE STOBBE CONDENSATION [J].

JOHNSON, WS ;

MCCLOSKEY, AL ;

DUNNIGAN, DA .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1950, 72 (01) :514-517

[10] Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects [J].

Kim, Hyung-Keun ;

Park, Soo-Heon ;

Cheung, Dae-Young ;

Cho, Young-Seok ;

Kim, Jin-Il ;

Kim, Sung-Soo ;

Chae, Hiun-Suk ;

Kim, Jae-Kwang ;

Chung, In-Sik .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (10) :1618-1625

← 1 2 3 →